Literature DB >> 2390477

1,2-dithiol-3-thione and dithioester analogues: potential radioprotectors.

B A Teicher1, J Stemwedel, T S Herman, P K Ghoshal, A Rosowsky.   

Abstract

Several 1,2-dithiol-3-thione and dithioester compounds were assayed for radioprotective capabilities in EMT6 cells in vitro. The 1,2-dithiol-3-thiones were generally more cytotoxic than the dithioesters and in some instances were more cytotoxic toward hypoxic cells than toward normally oxygenated cells. When the drugs were present at a concentration of 500 microM for 1 h prior to and during radiation delivery, the 5-(2-thienyl)-1,2-dithiol-3-thione produced a radiation protection factor (RPF) of 2.7 at 1 log of cell kill. The 4-methyl analogue of this same compound was, however, much less effective, producing a RPF of only 1.2. The 4-ethoxycarbonyl analogue was moderately active, producing a RPF of 1.7. The 4-methyl-5-(2-pyrazinyl)-1,2-dithiol-3-thione (Oltipraz) was least effective, yielding a RPF of only 1.1. Of the dithioesters tested, methyl 3-pyrrolidino-2-phenylpropene dithiocarboxylate produced a RPF of 2.6, methyl 3-piperidino-2-phenylpropenedithiocarboxylate a RPF of 2.7, and the corresponding 3-morpholino and 3-thiomorpholino derivatives RPF values of 2.7 and 2.9, respectively. The iodide salt of 4-ethoxycarbonyl-5-(2-thienyl)-1,2-dithiol-3-thione produced a RPF of 2.6 Methyl 3-cyclohexylamino-2-phenylpropenedithiocarboxylate was equally effective (RPF = 2.6). Finally, methyl 3-morpholino-3-thienyl-2-methylpropenedithiocarboxylate and methyl 3-morpholino-3-(2-pyrazinyl)-2-methylpropenedithiocarboxylate were less effective, producing RPF values of 2.0 and 1.6, respectively. These results demonstrate that several of these compounds are highly effective radioprotectors. In vitro and in vivo studies testing their efficacy are underway.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2390477      PMCID: PMC1971736          DOI: 10.1038/bjc.1990.221

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  Protection by WR-2721 of human bone marrow function following irradiation.

Authors:  L S Constine; G Zagars; P Rubin; M Kligerman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-08       Impact factor: 7.038

Review 2.  The chemotherapy of schistosomiasis.

Authors:  S Archer
Journal:  Annu Rev Pharmacol Toxicol       Date:  1985       Impact factor: 13.820

3.  Dithiolthione-induced alterations in hepatic glutathione and related enzymes in male mice.

Authors:  M H Davies; A M Blacker; R C Schnell
Journal:  Biochem Pharmacol       Date:  1987-02-15       Impact factor: 5.858

4.  Biochemical effects of dithiolthiones.

Authors:  S S Ansher; P Dolan; E Bueding
Journal:  Food Chem Toxicol       Date:  1986-05       Impact factor: 6.023

5.  Inhibitory effects of 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (Oltipraz) on carcinogenesis induced by benzo[a]pyrene, diethylnitrosamine and uracil mustard.

Authors:  L W Wattenberg; E Bueding
Journal:  Carcinogenesis       Date:  1986-08       Impact factor: 4.944

6.  Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-ones.

Authors:  T W Kensler; P A Egner; P M Dolan; J D Groopman; B D Roebuck
Journal:  Cancer Res       Date:  1987-08-15       Impact factor: 12.701

7.  Antitumor and radiosensitizing activity of several platinum-(+) dye complexes.

Authors:  B A Teicher; S A Holden
Journal:  Radiat Res       Date:  1987-01       Impact factor: 2.841

8.  1,2-Dithiol-3-thione analogs: effects on NAD(P)H:quinone reductase and glutathione levels in murine hepatoma cells.

Authors:  M J De Long; P Dolan; A B Santamaria; E Bueding
Journal:  Carcinogenesis       Date:  1986-06       Impact factor: 4.944

9.  Radiosensitization of EMT6 cells by four platinum complexes.

Authors:  B A Teicher; S Rockwell; J B Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  1985-05       Impact factor: 7.038

10.  The antischistosomal activity of oltipraz.

Authors:  E Bueding; P Dolan; J P Leroy
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1982-08
View more
  1 in total

1.  Clinical pharmacology studies of oltipraz--a potential chemopreventive agent.

Authors:  N V Dimitrov; J L Bennett; J McMillan; M Perloff; C M Leece; W Malone
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.